Cognitive Decline and Treatment Strategies in Multiple Sclerosis Patients

Review Data

Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for

researchers?

A: Good

Abstract & Keywords

Q: Are all required components included in the abstract? Are the keywords appropriately chosen?

A: Very good

Goal

Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?

A: Good

Structure

Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?

A: Good

Tools and Methods

Q: Are methods the author uses adequate and well used?

A: Good

Discussion & Conclusion

Q: Is it related to the results presented before? Do you consider them as coherent?

A: Very good

Comments:

The Conclusion section covers the clinical manifestations as well as provides an apt analysis of the cognitive impairment treatment strategies for multiple sclerosis (MS) patients. Further research is required to identify sensitive, specific and inexpensive biomarkers for assessing therapeutic efficacy.

Literature

Q: Does the author utilize relevant literature?

A: Very good

Author's knowledge

Q: What is the level of author’s knowledge? Does the author utilize all recent contributions relevant to the topic?

A: Very good

Length

Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?

A: Good

Figures & Tables

Q: Does the author use them suitably? Are legend and notations clear?

A: Insufficient

Writing style

Q: Is it clear and understandable?

A: Good

Further comments on the paper

Comments: This review article highlights the importance of cognitive function assessment for multiple sclerosis (MS) patients which is a valuable tool for monitoring disease prognosis. It not only discusses the wide range of cognitive impairment treatment strategies but also focuses on the drawbacks with reference to relevant literature. The effect of the neuropsychological batteries used for diagnostic and therapeutic purposes still remains very much limited, especially due to the validations and standardization issues. Predictive biomarkers of therapeutic response are needed to be identified and validated in order to diagnose cognitive decline and to improve the cognitive impairment in MS patients. The name of the scientist “Pliskin” was misspelled in the text section of the manuscript.

Q: Would you recommend this manuscript for further publication?

A: Yes - Suitable to be published

If you have any questions and clarifications you can write to the journal.

Thanks,
Science Repository Team